Seminars in Arthritis and Rheumatism
Volume 40, Issue 3 , Pages e3-e5 , December 2010

Leishmaniasis and Biologic Therapies for Rheumatologic Diseases

  • Antonio Cascio, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Antonio Cascio, MD, PhD, UO Medicina Tropicale e Parassitologia, Policlinico “G. Martino”, Via Consolare Valeria n. 1, 98125 Messina, Italia

References 

  1. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2008;
  2. Romani-Costa V, Sanchez C, Moya F, Estany C. [Visceral leishmaniasis related to infliximab administration]. Enferm Infecc Microbiol Clin. 2004;22:310
  3. Fabre S, Gibert C, Lechiche C, Dereure J, Jorgensen C, Sany J. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol. 2005;23:891–892
  4. Bagalas V, Kioumis I, Argyropoulou P, Patakas D. Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol. 2007;26:1344–1345
  5. Bassetti M, Pizzorni C, Gradoni L, Del Bono V, Cutolo M, Viscoli C. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology (Oxford). 2006;45:1446–1448
  6. Kone-Paut I, Retornaz K, Garnier JM, Bader-Meunier B. Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (Anakinra). Clin Exp Rheumatol. 2007;25:119
  7. Tektonidou MG, Skopouli FN. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: Reactivation of a latent infection?. Clin Rheumatol. 2008;27:541–542
  8. Garcia-Vidal C, Rodriguez-Fernandez S, Teijon S, Esteve M, Rodriguez-Carballeira M, Lacasa JM, et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis. 2009;28:331–337
  9. Balato A, Balato N, Patruno C, Gallo L, Ayala F. Visceral leishmaniasis infection in a patient with psoriasis treated with efalizumab. Dermatology. 2008;217:360–361
  10. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg. 2001;95:239–243
  11. Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis. 1986;154:1003–1011
  12. Desjeux P, Alvar J. Leishmania/HIV co-infections: Epidemiology in Europe. Ann Trop Med Parasitol. 2003;97(Suppl 1):3–15
  13. Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008;8:191–199
  14. Murray HW. Tissue granuloma structure-function in experimental visceral leishmaniasis. Int J Exp Pathol. 2001;82:249–267
  15. Vardy DA, Cohen A, Kachko L, Zvulunov A, Frankenburg S. Relapse of cutaneous leishmaniasis in a patient with an infected subcutaneous rheumatoid nodule. Br J Dermatol. 1999;141:914–917
  16. Zanaldi H, Rosenthal E, Marty P, Chichmanian RM, Pesce A, Cassuto JP. [Visceral leishmaniasis associated with Wegener disease. Use of lipid complex amphotericin B and liposomal amphotericin B]. Presse Med. 1999;28:959–961
  17. Sirianni MC, Barbone B, Monarca B, Nanni M, Lagana B, Aiuti F. A case of Behcet's disease complicated by visceral Leishmaniasis and myelodysplasia: Clinical considerations. Haematologica. 2001;86:1004–1005
  18. Baixauli Rubio A, Rodriguez Gorriz E, Campos Fernandez C, Calvo Catala J, Garcia Vicente S. [Rare opportunistic disease in a patient treated with immunosuppressive therapy for rheumatoid arthritis]. An Med Interne. 2003;20:276–277
  19. Scatena P, Messina F, Gori S, Ruocco L, Vignali C, Menichetti F, et al. Visceral leishmaniasis in a patient treated for polyarteritis nodosa. Clin Exp Rheumatol. 2003;21:S121–S123
  20. Sollima S, Corbellino M, Piolini R, Calattini S, Imparato S, Antinori S. Visceral leishmaniasis in a patient with Wegener's granulomatosis. Rheumatology (Oxford). 2004;43:935–937
  21. Venizelos I, Tatsiou Z, Papathomas TG, Orazi A. Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate. Int J Infect Dis. 2008;

 There was no financial support for this research.

 The authors have no conflicts of interest to declose.

PII: S0049-0172(09)00089-4

doi: 10.1016/j.semarthrit.2009.07.001

Seminars in Arthritis and Rheumatism
Volume 40, Issue 3 , Pages e3-e5 , December 2010

Article Tools